References
- [cited 2020 Sep 3]. Available from: https://www.merriam-webster.com/dictionary/the%20show%20must%20go%20on
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
- [cited 2021 Jan 16]. Available from: https://coronavirus.jhu.edu/
- [cited 2020 Sep 3]. Available from: https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-coronavirus-3-18-2020.pdf?fbclid=IwAR1W4E21-xZbEJdSG-RFewVZmuM72GGhiE2QIRyur_CPStp14uAa8gzhRXw#:~:text=On%20March%2011%2C%202020,COVID%2D19%20Outbreak
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323(13):1239.
- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059.
- Böhm M, Frey N, Giannitsis E, et al. Coronavirus disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation [published online ahead of print, 2020 May 27]. Clin Res Cardiol. 2020:1–14.
- Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–681.
- Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113.
- Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227.
- Khera A, Baum SJ, Gluckman TJ, et al. Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: a scientific statement from the American Society for Preventive Cardiology. Am J Prev Cardiol. 2020;1:100009.
- Raymond E, Thieblemont C, Alran S, et al. Impact of the COVID-19 outbreak on the management of patients with cancer. Target Oncol. 2020;15(3):249–259.
- [cited 2021 Jan 16]. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/haematological-malignancies-multiple-myeloma-in-the-covid-19-era
- Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34:2000–2011.
- Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44.
- Information for clinicians on investigational therapeutics for patients with COVID-19. 2020 Dec 4 [cited 2021 Jan 22]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
- Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4:1307–1310.
- Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020;13:94.
- Hultcrantz M, Richter J, Rosenbaum CA, et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York city: a cohort study from five academic centers. Blood Cancer Discov. 2020 Nov 1;1(3):234–243.
- Chari A, Kemal Samur M, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033–3040.